Inspire Medical Systems Reports Third Quarter 2026 Financial Results

Inspire Medical Systems reported third-quarter 2026 revenue of $206.7 million and adjusted diluted EPS of $0.14, with U.S. performance exceeding expectations despite coding and reimbursement headwinds. The company said Project Horizon will redirect investment toward high-impact revenue growth initiatives, alongside continued education efforts. The AMA CPT Editorial Panel approved new Category I codes for single-lead hypoglossal nerve stimulation, including the Inspire V system, effective January 1, 2028. The article did not report a stock-price movement.